Chirurgische Therapieoptionen bei Lebermetastasen

Kernaussagen

Chirurgische Resektabilität

• Aufgrund der Weiterentwicklung von chirurgischen Techniken, Chemotherapieprotokollen und perioperativer Behandlung stellen metastasierte Tumorleiden heute nicht mehr primär eine Palliativsituation für den Patienten dar. Eine chirurgische Resektion von Metastasen kann heute zu einer deutlichen Prognoseverbesserung für den Patienten führen.

• Durch einen Paradigmenwechsel in der Therapie kolorektaler Lebermetastasen sind heute nicht mehr Größe und Anzahl der Metastasen für die Indikationsstellung entscheidend, sondern vielmehr die Möglichkeit einer R0-Resektion und ein ausreichend großer verbleibender Leberrest. Es zählt, was bleibt.

Multimodale Therapiekonzepte

• Es wurde gezeigt, dass durch multimodale Therapiekonzepte auch primär nicht resektable Metastasen in ein resezierbares Stadium überführt werden können.

• Patienten mit metastasierten Tumorleiden sollten immer in einem interdisziplinären Tumorboard vorgestellt werden, damit ein individueller Therapieplan erstellt werden kann.

Literatur

• 1 Bechstein W O, Golling M. Standard surgical resection of colorectal liver metastases.  Chirurg. 2005;  76 543-551
• 2 Kopetz S, Chang G J, Overman M J et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.  J Clin Oncol. 2009;  27 3677-3683
• 3 Neumann U P, Seehofer D, Neuhaus P. The surgical treatment of hepatic metastases in colorectal carcinoma.  Dtsch Arztebl Int. 2010;  107 335-342
• 4 Bentrem D J, Dematteo R P, Blumgart L H. Surgical therapy for metastatic disease to the liver.  Annu Rev Med. 2005;  56 139-156
• 5 Poston G J, Adam R, Alberts S et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer.  J Clin Oncol. 2005;  23 7125-7134
• 6 Schmiegel W, Pox C, Reinacher-Schick A et al. S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII).  Z Gastroenterol. 2010;  48 65-136
• 7 Joyce D L, Wahl R L, Patel P V et al. Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases.  Arch Surg. 2006;  141 1220-1226 discussion 1227
• 8 Ruers T J, Wiering B, van der Sijp J R et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study.  J Nucl Med. 2009;  50 1036-1041
• 9 Jones O M, Rees M, John T G et al. Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection.  Br J Surg. 2005;  92 1165-1168
• 10 Hofmann W P, Radle J, Moench C et al. Prediction of perioperative mortality in patients with advanced liver disease and abdominal surgery by the use of different scoring systems and tests.  Z Gastroenterol. 2008;  46 1283-1289
• 11 Jarnagin W R, Conlon K, Bodniewicz J et al. A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases.  Cancer. 2001;  91 1121-1128
• 12 Nordlinger B, Van Cutsem E, Gruenberger T et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel.  Ann Oncol. 2009;  20 985-992
• 13 Van Cutsem E, Nordlinger B, Adam R et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.  Eur J Cancer. 2006;  42 2212-2221
• 14 Fong Y, Fortner J, Sun R L et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.  Ann Surg. 1999;  230 309-318 discussion 318–321
• 15 Nordlinger B, Guiguet M, Vaillant J C et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie.  Cancer. 1996;  77 1254-1262
• 16 Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40 983): a randomised controlled trial.  Lancet. 2008;  371 1007-1016
• 17 Mentha G, Majno P E, Andres A et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary.  Br J Surg. 2006;  93 872-878
• 18 Masi G, Loupakis F, Pollina L et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.  Ann Surg. 2009;  249 420-425
• 19 Gruenberger B, Tamandl D, Schueller J et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.  J Clin Oncol. 2008;  26 1830-1835
• 20 Folprecht G, Gruenberger T, Bechstein W O et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.  Lancet Oncol. 2010;  11 38-47
• 21 Benoist S, Brouquet A, Penna C et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?.  J Clin Oncol. 2006;  24 3939-3945
• 22 Tanaka K, Takakura H, Takeda K et al. Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases.  Ann Surg. 2009;  250 935-942
• 23 Hubert C, Fervaille C, Sempoux C et al. Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases.  Surgery. 2010;  147 185-194
• 24 Karoui M, Penna C, Amin-Hashem M et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.  Ann Surg. 2006;  243 1-7
• 25 Beal I K, Anthony S, Papadopoulou A et al. Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy.  Br J Radiol. 2006;  79 473-478
• 26 Shaw I M, Rees M, Welsh F K et al. Repeat hepatic resection for recurrent colorectal liver metastases is associated with favourable long-term survival.  Br J Surg. 2006;  93 457-464
• 27 Limmer S, Oevermann E, Killaitis C et al. Sequential surgical resection of hepatic and pulmonary metastases from colorectal cancer.  Langenbecks Arch Surg. 2010;  395 1129-1138
• 28 Mentha G, Roth A D, Terraz S et al. „Liver first” approach in the treatment of colorectal cancer with synchronous liver metastases.  Dig Surg. 2008;  25 430-435
• 29 Welsh F K, Tilney H S, Tekkis P P et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing.  Br J Cancer. 2007;  96 1037-1042
• 30 Kemeny N E, Jarnagin W R, Capanu M et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer.  J Clin Oncol. 2011;  29 884-889
• 31 Shimada H, Tanaka K, Endou I et al. Treatment for colorectal liver metastases: a review.  Langenbecks Arch Surg. 2009;  394 973-983